Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 3035-3040

  Pillai, Satish K ^a,b   Abdel Mohsen, Mohamed ^a   Guatelli, John ^c   Skasko, Mark ^c   Monto, Alexander ^a,b   Fujimoto, Katsuya ^b   Yukl, Steven ^a,b   Greene, Warner C ^a,d   Kovari, Helen ^e   Rauch, Andri ^f   Fellay, Jacques ^g   Battegay, Manuel ^h   Hirschel, Bernard ⁱ   Witteck, Andrea ^j   Bernasconi, Enos ^k   Ledergerber, Bruno ^e   Günthard, Huldrych F ^e   Wong, Joseph K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^k REGIONAL HOSPITAL OF LUGANO   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BONE MARROW STROMAL CELL ANTIGEN 2; CELL ANTIGEN; MESSENGER RNA; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG; VIRAL PROTEIN U; VIRUS PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS LOAD; VIRUS MUTATION;

AMINO ACID SEQUENCE; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; EVOLUTION, MOLECULAR; GPI-LINKED PROTEINS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INTERFERON-ALPHA; MOLECULAR SEQUENCE DATA; MUTATION; RIBAVIRIN; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIREMIA;

EID: 84857374815     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1111573109     Document Type: Article

References (57)

1. Piot P, Bartos M, Ghys PD, Walker N, Schwartländer B (2001) The global impact of HIV/AIDS. Nature 410:968-973. (Pubitemid 32335847)
2. Münk C, Brandt SM, Lucero G, Landau NR (2002) A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci USA 99:13843-13848. (Pubitemid 35215468)
3. Cowan S, et al. (2002) Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci USA 99:11914-11919. (Pubitemid 34994498)
4. Simon JH, Gaddis NC, Fouchier RA, Malim MH (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 4:1397-1400. (Pubitemid 28553462)
5. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
6. Neil SJ, Zang T, Bieniasz PD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. (Pubitemid 351158893)
7. Liberatore RA, Bieniasz PD (2011) Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci USA 108:18097-18101.
8. Stremlau M, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853. (Pubitemid 38297747)
9. Towers G, et al. (2000) A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci USA 97:12295-12299.
10. McNatt MW, et al. (2009) Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5:e1000300.
11. Sawyer SL, Wu LI, Emerman M, Malik HS (2005) Positive selection of primate TRI-M5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci USA 102:2832-2837. (Pubitemid 40299877)
12. Sawyer SL, Emerman M, Malik HS (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2:E275.
13. Kaiser SM, Malik HS, Emerman M (2007) Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein. Science 316:1756-1758. (Pubitemid 46988552)
14. Neil S, Bieniasz P (2009) Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 29:569-580.
15. Bishop KN, et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14:1392-1396. (Pubitemid 39081643)
16. Zheng YH, et al. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78:6073-6076.
17. Albin JS, Harris RS (2010) Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: Implications for therapeutics. Expert Rev Mol Med 12:e4.
18. Yu Q, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11:435-442. (Pubitemid 38568947)
19. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12:591-601. (Pubitemid 37222482)
20. Lecossier D, Bouchonnet F, Clavel F, Hance AJ (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112. (Pubitemid 36583087)
21. Nathans R, et al. (2008) Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol 26: 1187-1192.
22. Khoury G, Ewart G, Luscombe C, Miller M, Wilkinson J (2010) Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother 54:835-845.
23. Ejima T, Hirota M, Mizukami T, Otsuka M, Fujita M (2011) An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzymecatalytic polypeptide-like 3G. Int J Mol Med 28:613-616.
24. Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147:258-267.
25. Stetson DB, Medzhitov R (2006) Type I interferons in host defense. Immunity 25: 373-381. (Pubitemid 44354218)
26. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS (1989) Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science 244:575-577. (Pubitemid 19140811)
27. Aguilar Marucco D, et al. (2007) Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. J Antimicrob Chemother 59:565-568.
28. Torriani FJ, et al.; APRICOT Study Group (2004) Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351:438-450. (Pubitemid 38988593)
29. Asmuth DM, et al.; AIDS Clinical Trials Group A5192 Team (2010) Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: A phase II clinical trial. J Infect Dis 201:1686-1696.
30. Tanaka Y, et al. (2006) Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem Biophys Res Commun 341:314-319. (Pubitemid 43152108)
31. Chen K, et al. (2006) Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 80: 7645-7657. (Pubitemid 44092585)
32. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM (2006) Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 203:41-46.
33. Schoeni-Affolter F, et al.; Swiss HIV Cohort Study (2010) Cohort profile: The Swiss HIV Cohort study. Int J Epidemiol 39:1179-1189.
34. Taffé P, May M; Swiss HIV Cohort Study (2008) A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. Stat Med 27:4835-4853.
35. Liddament MT, Brown WL, Schumacher AJ, Harris RS (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14:1385-1391. (Pubitemid 39081642)
36. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN (2008) Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 82:3125-3130. (Pubitemid 351329200)
37. Suspène R, Rusniok C, Vartanian JP, Wain-Hobson S (2006) Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34: 4677-4684. (Pubitemid 44605614)
38. Vignuzzi M, Stone JK, Andino R (2005) Ribavirin and lethal mutagenesis of poliovirus: Molecular mechanisms, resistance and biological implications. Virus Res 107:173-181. (Pubitemid 40093090)
39. Estrabaud E, et al. (2007) Regulated degradation of the HIV-1 Vpu protein through a betaTrCP-independent pathway limits the release of viral particles. PLoS Pathog 3:e104.
40. Vigan R, Neil SJ (2010) Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol 84:12958-12970.
41. SkaskoM, et al. (2011) BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: Evidence for a post-ER mechanism of Vpu-action. Virology 411:65-77.
42. Rempel H, Sun B, Calosing C, Pillai SK, Pulliam L (2010) Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS 24:1415-1423.
43. Holmes RK, Koning FA, Bishop KN, Malim MH (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282:2587-2595. (Pubitemid 47076764)
44. Liberatore RA, Bieniasz PD (2011) Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci USA 108:18097-18101.
45. Mulder LC, Harari A, Simon V (2008) Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci USA 105:5501-5506. (Pubitemid 351753892)
46. Pillai SK, Wong JK, Barbour JD (2008) Turning up the volume on mutational pressure: Is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 5:26.
47. Mussil B, Sauermann U, Motzkus D, Stahl-Hennig C, Sopper S (2011) Increased APOBEC3G and APOBEC3F expression is associated with low viral load and prolonged survival in simian immunodeficiency virus infected rhesus monkeys. Retrovirology 8:77.
48. Casartelli N, et al. (2010) Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 6:e1000955.
49. Jolly C, Booth NJ, Neil SJ (2010) Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 84:12185-12199.
50. Skaug B, Chen ZJ (2010) Emerging role of ISG15 in antiviral immunity. Cell 143: 187-190.
51. Suspène R, et al. (2005) Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 102:8321-8326. (Pubitemid 40800087)
52. Douglas JL, et al. (2010) The great escape: Viral strategies to counter BST-2/tetherin. PLoS Pathog 6:e1000913.
53. Vandesompele J, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
54. Corpet F (1988) Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16:10881-10890.
55. Rose PP, Korber BT (2000) Detecting hypermutations in viral sequences with an emphasis on G - → A hypermutation. Bioinformatics 16:400-401. (Pubitemid 30417085)
56. Pond SL, Frost SD, Muse SV (2005) HyPhy: Hypothesis testing using phylogenies. Bioinformatics 21:676-679.
57. de Oliveira T, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21:3797-3800.